AI Article Synopsis
- The study investigated the effects of both syngeneic (from the same species) and allogeneic (from a different species) adipose tissue-derived stem cells in treating autoimmune thyroiditis in mice, showing promising therapeutic outcomes for both types.
- It was found that both stem cell types effectively reduced autoantibodies, decreased inflammation, and restored immune balance without negative side effects, although they led to different immune responses based on their origin.
- The results highlight that the location where stem cells migrated (mostly to the spleen) suggests their role in systemic immune modulation rather than direct targeting of the thyroid, reinforcing the potential of stem cell therapy for autoimmune conditions.
Article Abstract
Previously, we found that the intravenous administration of human adipose tissue-derived mesenchymal stem cells was a promising therapeutic option for autoimmune thyroiditis even when the cells were transplanted into a xenogeneic model without an immunosuppressant. Therefore, we explored the comparison between the therapeutic effects of syngeneic and allogeneic adipose tissue-derived stem cells on an experimental autoimmune thyroiditis mouse model. Experimental autoimmune thyroiditis was induced in C57BL/6 mice by immunization with porcine thyroglobulin. Adipose tissue-derived stem cells derived from C57BL/6 mice (syngeneic) or BALB/c mice (allogeneic) or saline as a vehicle control were administered intravenously four times weekly. Blood and tissue samples were collected 1 week after the last transplantation. Adipose tissue-derived stem cells from mice were able to differentiate into multiple lineages in vitro; however, mouse adipose tissue-derived stem cells did not have immunophenotypes identical to those from humans. Syngeneic and allogeneic administrations of adipose tissue-derived stem cells reduced thyroglobulin autoantibodies and the inflammatory immune response, protected against lymphocyte infiltration into the thyroid, and restored the Th1/Th2 balance without any adverse effects. However, different humoral immune responses were observed for infused cells from different stem cell sources. The strongest humoral immune response was induced by xenogeneic transplantation, followed by allogeneic and syngeneic administration, in that order. The stem cells were mostly found in the spleen, not the thyroid. This migration might be because the stem cells primarily function in systemic immune modulation, due to being given prior to disease induction. In this study, we confirmed that there were equal effects of adipose tissue-derived stem cells in treating autoimmune thyroiditis between syngeneic and allogeneic transplantations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3727/096368913X664586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrinsic Muscle Stem Cell Dysfunction Contributes to Impaired Regeneration in the mdx Mouse.
J Cachexia Sarcopenia Muscle
February 2025
Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Background: Duchenne muscular dystrophy (DMD) is a devastating disease characterized by progressive muscle wasting that leads to diminished lifespan. In addition to the inherent weakness of dystrophin-deficient muscle, the dysfunction of resident muscle stem cells (MuSC) significantly contributes to disease progression.
Methods: Using the mdx mouse model of DMD, we performed an in-depth characterization of disease progression and MuSC function in dystrophin-deficient skeletal muscle using immunohistology, isometric force measurements, transcriptomic analysis and transplantation assays.
Fibroblast Growth Factor 8 enhances the chondrogenesis of trunk neural crest cells: a possible gene regulatory network.
Int J Dev Biol
December 2024
Laboratory of Plasticity and Differentiation of Neural Crest Cells, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.
The neural crest (NC) is an embryonic cell population with high migratory capacity. It contributes to forming several organs and tissues, such as the craniofacial skeleton and the peripheral nervous system of vertebrates. Both pre-migratory and post-migratory NC cells are plastic, adopting multiple differentiation paths by responding to different inductive environmental signals.
View Article and Find Full Text PDFTrehalose Cryopreservation of Human Mesenchymal Stem Cells from Cord Tissue.
Biopreserv Biobank
December 2024
Coordinating Node, Andalusian Public Health System Biobank, Granada, Spain.
Adequate hypothermic storage of human mesenchymal stem cells (hMSCs) is of fundamental importance since they have been explored in several regenerative medicine initiatives. However, the actual clinical application of hMSCs necessitates hypothermic storage for long periods, a process that requires the use of non-toxic and efficient cryo-reagents capable of maintaining high viability and differentiating properties after thawing. Current cryopreservation methods are based on cryoprotectant agents (CPAs) containing dimethylsulphoxide (DMSO), which have been shown to be toxic for clinical applications.
View Article and Find Full Text PDFPrimary signet-ring cell carcinoma of the prostate involving the pelvis: a case report.
Front Oncol
December 2024
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Background: Signet-ring cell carcinoma (SRCC) originates from undifferentiated stem cells in the neck of glands within the lamina propria of the mucosa. Primarily affecting the stomach, SRCC can also involve the breast, pancreas, gallbladder, colon, and bladder, although these cases are rare. SRCC of the prostate is extremely rare, and diagnosing it pelvic puncture is particularly challenging.
View Article and Find Full Text PDFCell therapy in kidney diseases: advancing treatments for renal regeneration.
Front Cell Dev Biol
December 2024
Kidney Diseases and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan.
Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), pose a significant global health challenge, with high morbidity and mortality rates driven by rising prevalence of risk factors such as diabetes and hypertension. Current therapeutic strategies are often limited, prompting the exploration of advanced cell therapies as potential solutions. This review provides a comprehensive overview of the state of cell therapies in kidney disease, tracing the progression from preclinical studies to clinical applications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!